SCHEDULE: Spruce Street Capital Acquires 6.4% Stake in Yarrow Bioscience

Spruce Street Capital LP, along with its co-managing members Alex R. Rosen and Simon Basseyn, has reported beneficial ownership of 607,382 shares, representing 6.4% of Yarrow Bioscience, Inc.'s common stock.

Summary

• Spruce Street Capital LP, through its investment funds, has acquired a beneficial ownership of 607,382 shares of Yarrow Bioscience, Inc. common stock.
• This holding represents 6.4% of the total outstanding shares of Yarrow Bioscience, Inc.
• The filing indicates that Alex R. Rosen and Simon Basseyn, co-Managing Members of Spruce Street Capital GP LLC, are also reporting beneficial ownership.
• The shares were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.
• The total number of outstanding shares used for calculation is 9,437,693 as of September 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake acquisition by an investment manager. The lack of specific operational or financial updates limits a more enthusiastic sentiment.

Positives

• Significant investment by Spruce Street Capital LP, indicating confidence in Yarrow Bioscience's potential.
• The acquisition of a 6.4% stake suggests a notable position in the company.
• The filing confirms the shares were acquired in the ordinary course of business, implying a standard investment strategy.

Negatives

• The filing does not provide specific details on the acquisition price or the exact timing of the purchases.
• No operational or financial performance data for Yarrow Bioscience is included in this filing.

Risks

• Market volatility could impact the value of the acquired stake.
• Changes in Yarrow Bioscience's business performance could affect the investment's value.
• Potential for future stake adjustments by Spruce Street Capital LP.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or specific guidance regarding Yarrow Bioscience's future performance.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment managers, as reported in Schedule 13G filings, are common in the biotechnology sector. Such filings often precede or follow significant corporate events or reflect a strategic shift in investor sentiment towards a particular company.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, potentially leading to increased scrutiny or influence on company strategy.
• Management: May need to engage with Spruce Street Capital regarding their investment thesis and potential influence.
• Potential Investors: The filing may attract further investor attention to Yarrow Bioscience.

Next Steps

• Monitoring of Yarrow Bioscience's operational and financial performance.
• Observation of any further disclosures or actions by Spruce Street Capital LP regarding their stake.

Key Dates

Keywords

Yarrow Bioscience, Spruce Street Capital, Schedule 13G, Beneficial Ownership, Investment Manager, Common Stock, Shareholder